Biosimilars Advisory Service

October 2013

Biosimilars Advisory Service: Physician Perspectives On Erythropoiesis-Stimulating Agents, Insulin And Human Growth Hormone

Introduction:

Endocrinologists and nephrologists in Europe and Japan have had the opportunity to use biosimilar erythropoiesis-stimulating agents (ESAs) and human growth hormone (hGH) for several years, but the commercial success of these biosimilars has varied from country to country, as well as by drug class and manufacturer. To understand why the penetration of biosimilars is so variable, we surveyed endocrinologists and nephrologists in France and Germany about their familiarity with, and perception of, biosimilars, as well as other key topics pertinent to the biosimilar sector, such as pricing, reimbursement, automatic substitution, and indication extrapolation. This primary market research study also surveyed specialists in the United States, where the first biosimilars are expected to launch in the near future. By consolidating our findings from French, German, and U.S. physicians, we are able to draw meaningful conclusions about adoption rates of current and future biosimilars and provide highly granular brand and biosimilar market forecasts for the United States, Europe, and Japan.
This endocrinology- and nephrology-focused report is part of the Biosimilars Advisory Service. This service provides insight and analysis that is vital to successful business planning in the rapidly evolving biosimilar space. Quarterly Webinars detailing major developments, analyst insight addressing key market changes, therapeutic area-specific primary research, and forecasting modules are all included in a subscription to the Biosimilars Advisory Service. Rely on BioTrends to keep you up to date on the biosimilars landscape and poised to maximize opportunities for your business.

Questions Answered in This Report:

  *   Understand endocrinologists’ and nephrologists’ attitudes toward biosimilars
- How aware are endocrinologists and nephrologists of biosimilars?
- How similar are biosimilars and brands according to both of these specialists?
- What are the greatest hurdles for uptake of biosimilar versions of these agents?
- What level of clinical trial data will convince specialists that biosimilars and brands are comparable?
- What are physician opinions on indication extrapolation and pharmacy-level substitution?

  *   Understand how endocrinologists’ and nephrologists’ attitudes translate to expected use of biosimilars
- How quickly do endocrinologists and nephrologists expect to adopt biosimilars?
- How will price affect endocrinologists’ and nephrologists’ uptake of biosimilars?
- To what extent will cross-brand erosion from biosimilars occur?

  *   Forecast the anticipated uptake of biosimilar versions of erythropoiesis-stimulating agents, insulin analogues, and human growth hormone
- What is the expected patient share of biosimilar versions of major biologics prescribed in endocrinology and nephrology?
- At what price discounts will biosimilars for different brands enter the market, and how might this change?
- What is the annualized commercial potential for biosimilar versions of major biologics prescribed in endocrinology and nephrology?
- Will biosimilars steal a majority or minority market share?

Scope:

This report is based on a quantitative survey of 98 nephrologists and 94 endocrinologists in the United States, France and Germany

Markets Covered:

- United States, Europe, Japan

Primary Research:

- Quantitative 45-minute online survey of 98 nephrologists and 94 endocrinologists from the United States, France, and Germany

To qualify for participation, surveyed specialists had to meet the following criteria:

- Have worked in clinical practice for a minimum of 3 years and a maximum of 30 years.

- Work for a community hospital, private practice, or academic hospital (defined as having a large teaching facility).

- Spend more than 50% of their professional time in clinical practice if associated with an academic hospital or 75% of their professional time if based in a community hospital or private practice.

- Be familiar with the major erythropoiesis-stimulating agents, insulins, and growth hormones.

Deliverables:

- Final report in .ppt and .pdf format

- Detailed market forecasts at the brand and biosimilar level, split by US, EU5 and Japan in .xls format

- Live webinar highlighting key findings of the report and survey results

- Quarterly webinars analyzing major newsflow pertinent to the biosimi-lars industry

- Access to analysts to provide insight into the report

Report Dates:

- Publish: October 9,2013

Key Drugs Covered:

- Epoetin alfa, epoetin beta, darbepo-etin alfa, multiple insulins, somatropin

Companies Mentioned:

- Amgen

- Biocon

- Boehringer Ingelheim

- Eli Lilly

- Johnson & Johnson

- Novo Nordisk

- Sanofi

- Sandoz

- Kyowa Hakko Kirin

- Mylan

- Kissei

- JCR Pharmaceuticals

Key Terms for This Report:

- Automatic substitution

- Biobetter

- Biologic

- Biosimilar

- Endocrinology

- Nephrology

- Market access

- Pricing

- Reimbursement

- Indication extrapolation

Content Highlights:

- 10-year market forecasts

- Physicians Opinions of biosimilars

- Analyst support

- Quarterly analysis of biosimilars news

- Companion webinar

Related 2013 Products:

- Biosimilars Advisory Service: Physician Perspectives on Biosimilar G-CSFs and Monoclonal Antibodies in Oncology

- Biosimilars Advisory Service: Physician Perspectives on Pegylated IFN-a and TNF-a Inhibitors in Immune and Infectious Disease

- Biosimilars Advisory Service: Acceptance of Biosimilars Across Physician Specialties

- Biosimilars Advisory Service: US and EU Payer Perspectives

- Biosimilars Advisory Service: Corporate Strategies

- Biosimilars Advisory Service: Global Pipelines, Regulatory Pathways, and Key Stakeholder Perspectives of Biosimilars

Search Published Reports


Decision Resources Group brands include: